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C
ancer cells are characterized by aberrant pro-growth signal-
ing, usually induced upon ligand binding to their corre-
sponding receptor tyrosine kinases (RTKs), which are over-
expressed in many cancers.
1 Consequently, RTKs have become
prime therapeutic targets resulting in the development of speciﬁc
small molecules (e.g., erlotinib) and antibodies (e.g., cetuximab
and panitumumab) targeting epidermal growth factor receptors.
2
However, drug resistance is a clinical problem, and combination
therapy or the use of broader-spectrum RTK inhibitors (e.g.,
sorafenib and sunitinib), targeting vascular endothelial growth
factor (VEGF) receptor (VEGFR) and platelet-derived growth
factor receptor (PDGFR), may be more advantageous.
3 5 Alter-
natively, the ligands themselves may be targeted, which has led to
the development and FDA approval of an anti-VEGF-A antibody
(bevacizumab) for colorectal cancer treatment.
6,7 While studying
themechanismofactionofthemarinenaturalproductapratoxinA
(Figure1),
8 belongingto aclassofpotentcytotoxinsproducedby
marine cyanobacteria,
9 12 we have raised the possibility that
inhibition of the secretory pathway at the level of cotranslational
translocation by apratoxins and, in general, may be exploited for
anticancer therapy.
13 Inhibition of this process prevents export of
receptors and secretory molecules from the cytoplasm, leading to
receptor (including RTK) depletion and additionally should
prevent secretion of the corresponding ligands, growth factors,
and cytokines.
14 This one two punch is expected to have
unusually potent antiproliferative activity and may be an eﬀective
alternative to combination therapy with multiple (or broad-
spectrum) RTK and growth factor inhibitors and may be particu-
larly useful to treat cancers where autocrine loops, that is,
uncontrolled proliferation stimulated by secreted growth factors,
play a major role (e.g., colorectal cancer).
15 Here, we test this
hypothesis through a combination of medicinal chemistry based
on the apratoxin scaﬀold, molecular in vitro and in vivo pharma-
cology, and colorectal tumor xenograft eﬃcacy studies.
Since we found that apratoxin A activity was reversible,
13 it
became evident that apratoxins have to be administered on a
chronic schedule at a low dose rather than given as a bolus
injection; the latter was initially reported to cause toxicity without
signiﬁcantantitumoractivity.
8Ourpreliminarydataforchronic
administration of apratoxin A (Figure S3 in the Supporting
Information), recently conﬁrmed by others,
12 indicate that this
compound shows some antitumor eﬃcacy in vivo but is not well
tolerated.Thetherapeuticwindowissmall;wefounda50%death
rate (day 16) at the “therapeutic” concentration of 0.25 mg/kg
(daily ip) with irreversible toxicity occurring after 2 weeks of
treatment (Figure S3 in the Supporting Information). The main
question remained whether this toxicity is mechanism-related or
anoﬀ-targeteﬀect.Here,wedescribethesynthesisandbiological
evaluation of synthetic analogues of apratoxin A, one of which
showsgreaterpotencyandeﬃcacythantheparentcompoundand
is much better tolerated in vivo, providing the groundwork for
second-generation apratoxins with more promising anticancer
potential and validating this novel mechanism of action for cancer
therapy.
Our goal was 3-fold: We aimed (1) to deﬁne critical and
tunable elements for inhibition of cotranslational translocation,
(2) to extend our previous receptor studies and prove that
transport of receptors and their corresponding ligands are
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ABSTRACT: Apratoxins are cytotoxic marine natural products
that prevent cotranslational translocation early in the secretory
pathway. We showed that apratoxins downregulate receptors
and growth factor ligands, giving a one two punch to cancer
cells, particularly those that rely on autocrine loops. Through
total synthesis,we tested theeﬀectsof aminoacid substitutions,
including alanine scanning, on the downregulation of receptor
tyrosine kinases and vascular endothelial growth factor A (VEGF-A) and probed the stereospeciﬁcity of target engagement by
epimerizationofselectedchiralcenters.Diﬀerentialeﬀectsontwotypesofsecretorymoleculessuggestthattheapratoxins'substrate
selectivity with respect to inhibition of secretion may be tuned through structural modiﬁcations to provide tailored therapy. Our
structure activity relationship studies and medicinal chemistry eﬀorts led to a potent inhibitor with in vivo eﬃcacy in a colorectal
tumor xenograft model without irreversible toxicity exerted by apratoxin A, demonstrating that this novel mechanism of action has
therapeutic potential.
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inhibited by apratoxins, and (3) to design a synthetic analogue
with improved potency and less toxic side eﬀects in vivo. After
the report of the ﬁrst total synthesis,
16 structure activity
relationship (SAR) studies by other groups have focused on
thepolyketide(C33 C43)chain.
17,18Apratoxincytotoxicityis
highly sensitive to certain structural modiﬁcations to this unit.
Reversal of the conﬁguration at C37 from 37S to 37R or
removal of the methyl group at C37 abolished the antiproli-
ferative activity of apratoxins, shown for the oxazoline
analogue;
17 however, the C-34 epimer of apratoxin A showed
equipotentactivity.
18Dependingonthecellline,theC34 C35
dehydration product of apratoxin A possessed 12 29-fold
reduced cytotoxicity.
11 However, the potency of apratoxin E
(Figure 1), while also unsaturated at C34 C35, is only 6 15-
fold less cytotoxic than apratoxin A,
11 suggesting that the
modiﬁcation in the moCys unit (C27 C31), viz. removal of
the methyl group and/or α,β-unsaturation, may increase activ-
ity if the original, hydrated conﬁguration of C34 C35 as in
apratoxinAcanberestored.Wealsohypothesizedthattheα,β-
unsaturated system in the moCys unit may be responsible for
nonspeciﬁc( o ﬀ-target) toxicity due to conjugate addition of
cellular nucleophiles. Thus, we aimed to synthesize such an
apratoxin A/E hybrid (1e) with hopefully improved anticancer
activity and also tumor selectivity. Furthermore, we interro-
gated modiﬁcations in the peptide portion, where it is known
that lack of N-methylation of isoleucine reduces activity
(apratoxin B)
9 and replacement of proline by N-methyl alanine
largely retains activity (1a, apratoxin F)
12 (Figure 1). We
carried out an alanine scan (without changing the N-alkylation
pattern) and synthesized a valine analogue to more broadly
probe the hydrophobicity requirements of the R
3 position
(Ile f Val f Ala; Figure 1), which led to the ﬁrst synthesis of
the natural product apratoxin F (1a) and positional congeners
(1b d), providing new insight into the SAR of apratoxins.
Scheme1illustratesthemainsyntheticprocedurestoobtainthe
desired apratoxin analogues, closely paralleling reported synthesis
strategies and retrosynthetic analysis for apratoxin A with minor
modiﬁcations.
19,20Aldehyde2
19 21wastreatedwithRoush's(E)-
crotylboronate3
22togive4.Protectionofthehydroxylgroupwith
Troc gave 5, and removal of PMB group with DDQ, followed by
esteriﬁcation withFmoc-Pro-OH/Fmoc-N-Me-Ala-OH using the
Yamaguchimethod,
23providedester6.Ac id7wasobtainedwhen
6 was oxidized with OsO4/oxone/NaIO4 oxidation system.
24
Figure 1. Selected known apratoxins and synthetic targets 1a e
produced through alanine or valine incorporations within apratoxin A
at various positions (apratoxins F and S1 S3) or through “hybridiza-
tion” of apratoxins A and E (apratoxin S4). Me, methyl; Bu, butyl; Pr,
propyl; and PMB, p-methoxybenzyl. Two epimers of 1e (2-epi-1e,
apratoxin S5; and 34-epi-1e, apratoxin S6), minor reaction products
during 1e synthesis, were included in our SAR studies.
Scheme 1. Preparation of the Analogues of Apratoxin A
a
aReagents and conditions: (a) MS 4 Å, toluene,  78 C. (b) TrocCl,
DMAP, pyridine, CH2Cl2.( c )D D Q ,C H 2Cl2 H2O. (d) Cl3C6H2COCl,
DIEA, THF, DMAP, toluene. (e) OsO4,o x o n e ,N a I O 4.(f )H A T U ,D I E A ,
CH2Cl2.( g )P h 3P(O), Tf2O, CH2Cl2,0C. (h) Zn, NH4OAc, THF. (i)
Pd(PPh3)4, N-methylaniline, THF. (j) HATU, DIEA, CH2Cl2.( k )P d -
(PPh3)4, N-methylaniline, THF. (l) Et2NH, MeCN. (m) HATU, DIEA,
CH2Cl2. Troc, 2,2,2-trichloroethoxycarbonyl; DMAP, 4-(dimethylamino)-
pyridine;DDQ,2,3-dichloro-4,5-dicyanobenzoquinone;Fmoc,9-ﬂuorenyl-
methoxycarbonyl; Trt, triphenylmethyl; HATU, O-(7-azabenzotriazol-1-
yl)-N,N,N0,N0-tetramethyluronium hexaﬂuorophosphate; DIEA, diisopro-
pylethylamine; and Tf, triﬂuoromethylsulfonyl.863 dx.doi.org/10.1021/ml200176m |ACS Med. Chem. Lett. 2011, 2, 861–865
ACS Medicinal Chemistry Letters LETTER
Coupling of 6 with modiﬁed cysteine amine 8 gave the key
intermediates 9. Using the Kelly method (PPh3(O)/Tf2Oi n
CH2Cl2),
17,19,20,25 the thiazoline ring was formed, and Troc was
removedimmediatelythereafter.Subsequentremovalofallylfrom
10 with Pd(PPh3)4/N-methylaniline provided acid 11, which was
coupledwithtripeptide12(seetheSupportingInformation)using
HATU/DIEAtogiveprotectedlinearcompounds13.Cleavageof
O-allylesterbyPd(PPh3)4/N-methylanilineandremovalofFmoc
by Et2NH/MeCN aﬀorded cyclization precursors, whose ﬁnal
macrolactamization with HATU/DIEA under high dilution con-
centration provided apratoxins 1a e in 18 52% yield. We used
the same strategy to synthesize apratoxin A for direct comparison
in our biological assays.
WefoundthatapratoxinF(1a)wasthemostpotentapratoxin
A analogue that arose from an alanine scan; both compounds
showedcomparableeﬀectsonHCT116colorectalcarcinomacell
viability (Table 1) and met proto-oncogene (MET) receptor
levels (Figure 2a). In contrast, the other two alanine scan
“mutants” 1b and 1d exhibited strongly reduced activity in both
assays. Replacement of Ile with Val (1c) did not aﬀect activity.
However, apratoxin S4 (1e)—the apratoxin A/E hybrid
(Figure 1)—was superior as compared with all other apratoxins
(Figure 2a,b and Table 1), consistent with our hypothesis. As a
resultofsynthesisscale-up,wealsoidentiﬁedtwominorreaction
products that we characterized as 2-epi-1e and 34-epi-1e
(Figure 1 and see the Supporting Information), which we
included in our SAR studies. While 2-epi-1e lost activity by ca.
200-fold, the two34-epimers of 1e were almost equally active. In
allcases,cellviability(Table1)correlatedwellwiththereduction
of receptor levels based on immunoblot analysis (Figure 2a),
suggesting that the conﬁguration at C-2 is crucial for potent
cytotoxicity,whiletheC-34conﬁgurationisirrelevantasrecently
found for apratoxin A.
18
Next, we extended our SAR studies to our hypothesized
eﬀectsofapratoxinsongrowthfactorsecretionandfocusedon
the angiogenic drug target VEGF-A.
26 28 Indeed, all apratox-
insinhibitedthesecretionofVEGF-A(Table1andFigure2c),
conﬁrming our hypothesis that apratoxins prevent the export
of receptors and the secretion of ligands, which is also
consistent with our data for the antiangiogenic properties of
apratoxins.
29 Furthermore, depending on the apratoxin struc-
ture, the IC50 values were 2 20-fold lower than the IC50
values for cell viability, suggesting that VEGF-A is more
susceptible to inhibition of secretion as compared with
receptor proteins tested. This indicates that reducing levels
of VEGF-A (and likely other ligands)alone is not suﬃcient to
inhibit proliferation and that receptor depletion is a necessity.
This result also raises the possibility that the apratoxins'
substrate selectivity with respect to inhibition of secretion
may be tuned through structural modiﬁcations, which is a
subject of ongoing research in our laboratory.
Table 1. Activities of Apratoxins on HCT116 Cell Viability
and VEGF-A Secretion
apratoxin IC50 (nM)
a cell viability IC50 (nM)
b VEGF-A secretion
A 5.97 1.49
E 184 9.10
F( 1a) 4.92 0.461
S1 (1b) 373 20.7
S2 (1c) 4.13 0.322
S3 (1d) 1700 340
S4 (1e) 1.14 0.308
S5 (2-epi-1e) 258 112
S6 (34-epi-1e) 1.58 0.391
aDetermined after 48 h (n = 4).
bDetermined after 12 h (n = 3).
Figure 2. Cellular activity of apratoxins (HCT116 cells). (a) SAR by
immunoblot analysis for RTK levels (MET) after 24 h. Comparison
of apratoxin A and S4 (1e)e ﬀects on (b) cell viability (48 h, n = 4) and
(c) VEGF-A secretion (12 h, n = 3). Error bars indicate SD. (d) Dose-
dependent cell cycle eﬀects of 1e determined by DNA content analysis,
demonstrating induction of G1 arrest (24 h).864 dx.doi.org/10.1021/ml200176m |ACS Med. Chem. Lett. 2011, 2, 861–865
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We then tested our prioritized compound (1e)o nt h ec e l l
cycle to determine if its eﬀects parallel those of apratoxin A.
Consistent with data for apratoxin A,
29 dose-dependent DNA
content analysis of HCT116 cells upon 24 h of treatment
revealed that 1e increases the population of cells in G1 phase
concomitant with decrease of cells in S phase, starting at
subnanomolar concentrations (0.32 nM) with strongest eﬀect
at 3.2 nM (Figure 2d), which is the concentration range for the
inhibitionofVEGF-AandreceptorlevelsandalsoneartheIC50
for cell viability (Table 1). Next, we conﬁrmed that the
inhibitionofthesecretorypathwaybyapratoxinS4(1e)occurs
at the level of cotranslational translocation from the cytoplasm
to the endoplasmic reticlum.
13 We used in vitro translation
experiments in the presence of microsomal membranes to
demonstrate the inhibition by 1e of cotranslational processing
events characteristic for secretory molecules, speciﬁcally glyco-
sylation (using α-factor mRNA substrate) and signal peptide
cleavage (using β-lactamase mRNA substrate). Inhibition of
cotranslational processing in a dose-dependent manner is
consistent with the mode of action that we had reported for
apratoxinA(Figure3).
13WealsousedahumanreceptorcDNA
(PDGFR-β) and proved by coupled in vitro transcription/
translation that 1e inhibits processing of this cancer-associated
RTK (Figure 3).
Initial in vivo studies aimed at determining the maximum
tolerateddose(MTD)alreadysuggestedthat1eismuchbetter
tolerated in vivothanapratoxinA, whichis consistentwith our
hypothesisthattheconjugatedsystemmaybealiabilityinvivo.
While high doses (g0.375 mg/kg) of apratoxin A led to
irreversibletoxicity,thatis,continuedweightlossandeventual
death even when ip injection was discontinued, mice treated
with apratoxin S4 (1e) quickly recovered when high-dose
injections were stopped. Using the same low dose of 0.25
mg/kgof1e(dailyip for over 2weeks)used for apratoxin A to
treat HCT116 tumor-bearing nu/nu mice (Figure S3 in the
Supporting Information), the antitumor eﬀect was much
stronger (Figure 4a) without any evident toxicity based on
lack of weight loss and histological assessment of kidney and
liver tissue. To determine if the mechanism of action in vivo
correlateswithourinvitrodata,wemeasuredreceptorlevelsin
the tiny residual tumor tissue and found that VEGFR2 and
PDGFR-β levels were depleted (Figure 4b). In contrast, the
liver appeared less aﬀected, as we did not observe a signiﬁcant
reduction of VEGFR2 in this tissue of the same mice
( F i g u r e4 c ) ,w h i c hm a yi n d i c a t ep r e f e r e n t i a lu p t a k eo f1e by
the tumor and/or enhanced dependency of tumor on the
secretory pathway due to more rapid turnover and resynthesis
of receptor molecules.
Inconclusion,apratoxinS4(1e)istheﬁrstviablecandidate
of the apratoxin family that shows the requisite tumor
selectivity and increased antitumor activity and potency.
Thus, we have largely separated anticancer activity from
nonselective toxicity, indicating for the ﬁrst time that inhibi-
tion of cotranslational translocation is a promising novel
mechanism for cancer therapy, particularly to treat cancers
that are characterized by aberrant autocrine loops such as
colorectal cancer. Furthermore, our SAR studies suggest that
through structural modiﬁcation we may be able to tune
apratoxin selectivity toward certain substrates destined for
the secretory pathway, which may be exploited to provide
tailored therapy and also more selective chemical tools to
s t u d yt h es e c r e t o r yp a t h w a y .
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Figure 3. ApratoxinS4(1e)inhibits cotranslationalprocessing in vitro.
Products of in vitro translation reactions (rabbit reticulocyte, amino
acids, [
35S]methionine, canine pancreatic microsomal membranes,
mRNA template, and apratoxin 1e) were separated by SDS-PAGE to
autoradiographicallydetecteﬀectsontranslationandglycosylationofα-
factor and signal peptide cleavage of β-lactamase. When PDGFR-β
cDNA was used as a template, in vitro transcription/translation was
carried out using T7 TNT Quick Master Mix and glycosylation
determined by SDS-PAGE followed by autoradiography.
Figure 4. In vivo activity of apratoxin S4 (1e) using a HCT116
xenograft mouse model. (a) Eﬃcacy studies (daily ip). Subcutaneous
tumor-bearingmicewereinjectedwith1e(n=8)orDMSOvehicle(n=
10), and tumor volumes were monitored over time. Error bars indicate
SEM. (b) At the end of the eﬃcacy studies, tumors were analyzed by
immunoblot analysis for receptor levels. (c) Levels of VEGFR2 were
analogously measured in liver tissue of vehicle- vs 1e-treated mice.865 dx.doi.org/10.1021/ml200176m |ACS Med. Chem. Lett. 2011, 2, 861–865
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